Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Shingles | Research

Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan

Authors: Ryota Hase, Daisuke Suzuki, Cynthia de Luise, Haoqian Chen, Edward Nonnenmacher, Takakazu Higuchi, Kayoko Katayama, Mitsuyo Kinjo, Sadao Jinno, Toshitaka Morishima, Naonobu Sugiyama, Yoshiya Tanaka, Soko Setoguchi

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP).

Methods

VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases.

Results

Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM.

Conclusions

VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data.
Appendix
Available only for authorised users
Literature
2.
go back to reference Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, Jégou C, et al. Burden of herpes zoster in the Japanese population with immunocompromised/chronic disease conditions: results from a cohort study claims database from 2005–2014. Dermatol Ther (Heidelb). 2019;9:117–33.CrossRefPubMed Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, Jégou C, et al. Burden of herpes zoster in the Japanese population with immunocompromised/chronic disease conditions: results from a cohort study claims database from 2005–2014. Dermatol Ther (Heidelb). 2019;9:117–33.CrossRefPubMed
3.
go back to reference Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis. 2020;20:905.CrossRefPubMedPubMedCentral Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis. 2020;20:905.CrossRefPubMedPubMedCentral
4.
go back to reference Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168–76.CrossRefPubMed Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168–76.CrossRefPubMed
5.
go back to reference Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30:931–3.CrossRefPubMed Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30:931–3.CrossRefPubMed
6.
go back to reference Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.CrossRefPubMedPubMedCentral Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.CrossRefPubMedPubMedCentral
7.
go back to reference Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.CrossRefPubMedPubMedCentral Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.CrossRefPubMedPubMedCentral
8.
go back to reference Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17:213.CrossRefPubMedPubMedCentral Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17:213.CrossRefPubMedPubMedCentral
9.
go back to reference Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25:617–25.CrossRefPubMedPubMedCentral Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25:617–25.CrossRefPubMedPubMedCentral
10.
go back to reference Calderwood MS, Platt R, Hou X, Malenfant J, Haney G, Kruskal B, et al. Real-time surveillance for tuberculosis using electronic health record data from an ambulatory practice in eastern Massachusetts. Public Health Rep. 2010;125:843–50.CrossRefPubMedPubMedCentral Calderwood MS, Platt R, Hou X, Malenfant J, Haney G, Kruskal B, et al. Real-time surveillance for tuberculosis using electronic health record data from an ambulatory practice in eastern Massachusetts. Public Health Rep. 2010;125:843–50.CrossRefPubMedPubMedCentral
11.
go back to reference Trepka MJ, Beyer TO, Proctor ME, Davis JP. An evaluation of the completeness of tuberculosis case reporting using hospital billing and laboratory data; Wisconsin, 1995. Ann Epidemiol. 1999;9:419–23.CrossRefPubMed Trepka MJ, Beyer TO, Proctor ME, Davis JP. An evaluation of the completeness of tuberculosis case reporting using hospital billing and laboratory data; Wisconsin, 1995. Ann Epidemiol. 1999;9:419–23.CrossRefPubMed
12.
go back to reference Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011;20:229–35.CrossRefPubMed Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011;20:229–35.CrossRefPubMed
13.
go back to reference Yokoe DS, Coon SW, Dokholyan R, Iannuzzi MC, Jones TF, Meredith S, et al. Pharmacy data for tuberculosis surveillance and assessment of patient management. Emerg Infect Dis. 2004;10:1426–31.CrossRefPubMedPubMedCentral Yokoe DS, Coon SW, Dokholyan R, Iannuzzi MC, Jones TF, Meredith S, et al. Pharmacy data for tuberculosis surveillance and assessment of patient management. Emerg Infect Dis. 2004;10:1426–31.CrossRefPubMedPubMedCentral
14.
go back to reference Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86:1146-53. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86:1146-53.
15.
go back to reference Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1018–24.CrossRefPubMed Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1018–24.CrossRefPubMed
16.
go back to reference de Luise C, Sugiyama N, Morishima T, Higuchi T, Katayama K, Nakamura S, et al. Validity of claims-based algorithms for selected cancers in Japan: results from the VALIDATE-J study. Pharmacoepidemiol Drug Saf. 2021;30:1153–61.CrossRefPubMedPubMedCentral de Luise C, Sugiyama N, Morishima T, Higuchi T, Katayama K, Nakamura S, et al. Validity of claims-based algorithms for selected cancers in Japan: results from the VALIDATE-J study. Pharmacoepidemiol Drug Saf. 2021;30:1153–61.CrossRefPubMedPubMedCentral
17.
go back to reference Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefPubMed Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefPubMed
18.
go back to reference Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018;51:810–20.CrossRefPubMed Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018;51:810–20.CrossRefPubMed
19.
go back to reference International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200–8.CrossRef International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200–8.CrossRef
21.
go back to reference Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med. 2020;20:262.CrossRefPubMedPubMedCentral Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med. 2020;20:262.CrossRefPubMedPubMedCentral
22.
go back to reference Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res. 2023;21:88–99.CrossRefPubMed Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res. 2023;21:88–99.CrossRefPubMed
24.
go back to reference Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest. 2020;158:2323–32.CrossRefPubMed Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest. 2020;158:2323–32.CrossRefPubMed
25.
go back to reference Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1–ii64.CrossRefPubMed Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1–ii64.CrossRefPubMed
Metadata
Title
Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
Authors
Ryota Hase
Daisuke Suzuki
Cynthia de Luise
Haoqian Chen
Edward Nonnenmacher
Takakazu Higuchi
Kayoko Katayama
Mitsuyo Kinjo
Sadao Jinno
Toshitaka Morishima
Naonobu Sugiyama
Yoshiya Tanaka
Soko Setoguchi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08466-8

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine